An X-ray dosimeter has been investigated with the use of a charge injection type condenser. The detector is small size and it housed in an epoxy resin approximately 4.5×2.5× 1.5 mm. The X-ray dose can be determined by decreasing the amount of electron injected into floating gate through X-ray irradiation. The X-ray irradiation dose can be measured by decreasing of the capacitance. This dosimeter shows good linearity but the X-ray energy response for low energy region is higher than high energy region.
Prospective study of bone scintigraphy was performed on 414 patients with breast carcinoma and 88 patients with prostate carcinoma. In 468 of them, confirmative diagnoses of bone, whether metastasis was existent or not, were made after the observations over a year. Finally, the incidences of bone metastasis were 11 percent for breast carcinoma and 54 percent for prostate carcinoma respectively. The efficacy of preoperative bone scintigraphy in breast carcinoma was comparative to that in prostate carcinoma with regard to improvement of predictive probability of bone metastasis: raising up the probability in the positive cases and bringing down in the negative cases.
This paper describes a software package for a personal computer which deals with storage records of radioactive wastes; the software keeps the records of purchase and use of radioisotopes and makes the inventory records of radioactive wastes. The records for the cargo booking of the wastes for the Japanese Radioisotope Association can be prepared by this software package.
Bone metabolic markers were investigated in the male hemodialysis patients within and over 60 years old and the female hemodialysis patients within and over 50 years old. Our results indicated that bone metabolic markers were more increased in the lower values of serum estradiol in the male patients, but inversely were more enhanced in higher values of serum estradiol in the female patients.
The bone metabolic markers showed the significant differences in age and sex of the hemodialysis patients with renal insufficiency. It is likely that the evaluations of bone change and biochemical metabolic markers should be based on serum estradiol level, sex and age of the renal hemodialysis patients.